Publication of Form 20-F
Press Release
Publication of Form 20-F
Hong Kong, Shanghai & Florham Park, NJ: Tuesday, February 28, 2023: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today published the Form 20-F for the financial year ended December 31, 2022. This is available for viewing at http://www.rns-pdf.londonstockexchange.com/rns/3620R_1-2023-2-28.pdf and also on the website of the Company at www.hutch-med.com.
About HUTCHMED
HUTCHMED (Nasdaq/AІM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. Іt is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Іt has more than 5,000 personnel across all its companies, at the center of which is a team of about 1,800 in oncology/immunology. Since inception HUTCHMED has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three oncology drugs now approved and marketed in China. For more information, please visit: www.hutch‑med.com or follow us on LinkedIn .
CONTACTS
Investor Enquiries |
|
|
Mark Lee, Senior Vice President |
+852 2121 8200 |
|
Annie Cheng, Vice President |
+1 (973) 306 4490 |
|
|
|
Media Enquiries |
|
|
Americas - Brad Miles, Solebury Trout |
+1 (917) 570 7340 (Mobile) |
|
Europe - Ben Atwell / Alex Shaw, FTI Consulting |
+44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) |
|
Asia - Zhou Yi, Brunswick |
+852 9783 6894 (Mobile) |
|
|
|
Nominated Advisor |
|
|
Atholl Tweedie / Freddy Crossley,
|
+44 (20) 7886 2500 |
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 8 hours ago Rathbones Group
- 8 hours ago The Artisanal Spirits Company
- 9 hours ago Tritax Eurobox (EUR)
- 9 hours ago Videndum
- 9 hours ago Legal & General Group